SARS-CoV-2 replication in human ACE2-transgenic mice treated with daclatasvir
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP532907
下载链接
链接失效反馈官方服务：
资源简介：
We examined the HCV nonstructural protein 5A (NS5A) inhibitor daclatasvir for potential repurposing against SARS-CoV-2 infection in transgenic miceexpressing human ACE2 (K18-hACE-2 mouse strain). Based on molecular docking, enzymatic assays and cellular-based studies, evidence was provided in favor of the compound possessing anti-exonuclease activity. Daclatasvir induced error-prone in vivo replication, prevented lethal SARS-CoV-2 replication, reduced cell death and inflammatory responses at a concentration that could allow further clinical development against COVID-19.
创建时间：
2026-01-26
